Vitali Alexeev, PhD
Philadelphia, PA 19107
Most Recent Peer-reviewed Publications
- Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment
- Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa
- Reaction Chemistry Generated by Nanosecond Pulsed Dielectric Barrier Discharge Treatment is Responsible for the Tumor Eradication in the B16 Melanoma Mouse Model
- Fibulin-4 E57K knock-in mice recapitulate cutaneous, vascular and skeletal defects of recessive cutis laxa 1B with both elastic fiber and collagen fibril abnormalities
- The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice
PhD Cell Biology, Institute of Cytology, Russian Academy of Science - 1996
Professor, Microbiology & Immunology
Research and Clinical Interests
My current, vaccine-related research is focused on the analysis of the chemokines’ activity during immune response induction and on the development of chemokine-mediated strategies of immune response stimulation. My laboratory recently assessed the applicability of the secondary lymphoid chemokine, CCL21 for stimulation of melanoma-specific immune responses (Novak L, Igoucheva O, Cho S, Alexeev V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Molecular cancer therapeutics 2007;6 (6):1755-64). My laboratory is currently working on the development of practically applicable approaches for the treatment of cutaneous melanomas using chemokines in conjunction with (i) melanoma DNA vaccines and (ii) suicidal gene therapy.
In addition, I am collaborating with Dr. T. Sato (Department of Medical Oncology) on the research project related to the development on novel approaches of tumor-specific immune response induction using IL-10 antagonism.
The membership in the JVC will allow me to closely interact with researchers and clinicians, who are involved in the research, testing and application of anti-cancer vaccines, which potentially may lead to the establishment of new collaboration project. I believe, these interactions will also allow me to extend my knowledge in cancer vaccines and understanding of clinical needs.